(Q36734752)

16 August 2017

1 reference

title

Androgen receptor and prostate cancer (English)

1 reference

16 August 2017

1 reference

E Richter

1

1 reference

16 August 2017

S Srivastava

series ordinal

2

1 reference

16 August 2017

A Dobi

series ordinal

3

1 reference

16 August 2017

language of work or name

1 reference

13 February 2007

1 reference

Prostate Cancer and Prostatic Diseases

16 August 2017

published in

1 reference

16 August 2017

volume

10

1 reference

16 August 2017

issue

2

1 reference

16 August 2017

page(s)

114-118

1 reference

Molecular regulation of androgen action in prostate cancer

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

Androgen-induced expression of endoplasmic reticulum (ER) stress response genes in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

Androgen receptor binding sites identified by a GREF_GATA model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

Molecular biology of the androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

Localization of functional domains in the androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

21 January 2018

Heat shock protein 90.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

Molecular communication between androgen receptor and general transcription machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

Endocrine mechanisms of disease: Expression and degradation of androgen receptor: mechanism and clinical implication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

Androgen receptor coregulators in prostate cancer: mechanisms and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: Androgen-receptor cofactors and bypass pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

Regulatory processes affecting androgen receptor expression, stability, and function: potential targets to treat hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

Inactivation of androgen receptor coregulator ARA55 inhibits androgen receptor activity and agonist effect of antiandrogens in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

Involvement of arginine methyltransferase CARM1 in androgen receptor function and prostate cancer cell viability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

Dynamic methylation of histone H3 at lysine 4 in transcriptional regulation by the androgen receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

Locus-wide chromatin remodeling and enhanced androgen receptor-mediated transcription in recurrent prostate tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

Quantitative expression profile of androgen-regulated genes in prostate cancer cells and identification of prostate-specific genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

Identification and functional analysis of consensus androgen response elements in human prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

Prostate specific antigen gene regulation by androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

Medicine. Fused genes may help explain the origins of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

Nuclear receptors: integration of multiple signalling pathways through phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: Modifications to the androgen receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

The PTEN tumor suppressor is a negative modulator of androgen receptor transcriptional activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

Conditional expression of PTEN alters the androgen responsiveness of prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

Hyperthermia-induced proteasome inhibition and loss of androgen receptor expression in human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

The androgen receptor: a potential target for therapy of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

The correlation between pretreatment serum hormone levels and treatment outcome for patients with prostatic cancer and bony metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

Molecular determinants of resistance to antiandrogen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

Androgen regulates apoptosis induced by TNFR family ligands via multiple signaling pathways in LNCaP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

Molecular basis for the antiandrogen withdrawal syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

Structural basis for antagonism and resistance of bicalutamide in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

Arylisothiocyanato selective androgen receptor modulators (SARMs) for prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

Androgen Receptors in Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

inferred from DOI database lookup

7 January 2021

based on heuristic

Prohibitin, a protein downregulated by androgens, represses androgen receptor activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

inferred from DOI database lookup

7 January 2021

based on heuristic

LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500936

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.PCAN.4500936

1 reference

16 August 2017

1 reference